Nov 6 (Reuters) - U.S. drugmaker Eli Lilly and Co’s third-quarter profit more than doubled, led by higher demand for its newer treatments such as diabetes drug Trulicity and psoriasis medicine Taltz.
Net income rose to $1.15 billion or $1.12 per share in the three months ended Sept. 30, from $555.6 million or 53 cents per share a year earlier, Lilly said on Tuesday.
Lilly’s net income a year earlier was hurt by a write-down expense of more than $400 million.
Revenue rose about 7 percent to $6.06 billion. (Reporting by Aakash Jagadeesh Babu and Tamara Mathias in Bengaluru Editing by Sai Sachin Ravikumar)